Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Novel insights into the BAP1-inactivated melanocytic tumor

M. Donati, P. Martinek, P. Steiner, P. Grossmann, T. Vanecek, L. Kastnerova, I. Kolm, M. Baneckova, P. Donati, I. Kletskaya, A. Kalmykova, J. Feit, P. Blasch, D. Szilagyi, A. Baldi, P. Persichetti, A. Crescenzi, M. Michal, DV. Kazakov

. 2022 ; 35 (5) : 664-675. [pub] 20211202

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018628

BAP1-inactivated melanocytic tumor (BIMT) is a group of melanocytic neoplasms with epithelioid cell morphology molecularly characterized by the loss of function of BAP1, a tumor suppressor gene located on chromosome 3p21, and a mutually exclusive mitogenic driver mutation, more commonly BRAF. BIMTs can occur as a sporadic lesion or, less commonly, in the setting of an autosomal dominant cancer susceptibility syndrome caused by a BAP1 germline inactivating mutation. Owing to the frequent identification of remnants of a conventional nevus, BIMTs are currently classified within the group of combined melanocytic nevi. "Pure" lesions can also be observed. We studied 50 BIMTs from 36 patients. Most lesions were composed of epithelioid melanocytes of varying size and shapes, resulting extreme cytomorphological heterogeneity. Several distinctive morphological variants of multinucleated/giant cells were identified. Some hitherto underrecognized microscopic features, especially regarding nuclear characteristics included nuclear blebbing, nuclear budding, micronuclei, shadow nuclei, peculiar cytoplasmic projections (ant-bear cells) often containing micronuclei and cell-in-cell structures (entosis). In addition, there were mixed nests of conventional and BAP1-inactivated melanocytes and squeezed remnants of the original nevus. Of the 26 lesions studied, 24 yielded a BRAF mutation, while in the remaining two cases there was a RAF1 fusion. BAP1 biallelic and singe allele mutations were found in 4/22 and 16/24 neoplasms, respectively. In five patients, there was a BAP1 germline mutation. Six novel, previously unreported BAP1 mutations have been identified. BAP1 heterozygous loss was detected in 11/22 lesions. Fluorescence in situ hybridization for copy number changes revealed a related amplification of both RREB1 and MYC genes in one tumor, whereas the remaining 20 lesions studied were negative; no TERT-p mutation was found in 14 studied neoplasms. Tetraploidy was identified in 5/21 BIMTs. Of the 21 patients with available follow-up, only one child had a locoregional lymph node metastasis. Our results support a progression of BIMTs from a conventional BRAF mutated in which the original nevus is gradually replaced by epithelioid BAP1-inactivated melanocytes. Some features suggest more complex underlying pathophysiological events that need to be elucidated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018628
003      
CZ-PrNML
005      
20220804134922.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41379-021-00976-7 $2 doi
035    __
$a (PubMed)34857909
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Donati, Michele $u Department of Pathology, University Hospital Campus Bio-Medico, Rome, Italy $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic
245    10
$a Novel insights into the BAP1-inactivated melanocytic tumor / $c M. Donati, P. Martinek, P. Steiner, P. Grossmann, T. Vanecek, L. Kastnerova, I. Kolm, M. Baneckova, P. Donati, I. Kletskaya, A. Kalmykova, J. Feit, P. Blasch, D. Szilagyi, A. Baldi, P. Persichetti, A. Crescenzi, M. Michal, DV. Kazakov
520    9_
$a BAP1-inactivated melanocytic tumor (BIMT) is a group of melanocytic neoplasms with epithelioid cell morphology molecularly characterized by the loss of function of BAP1, a tumor suppressor gene located on chromosome 3p21, and a mutually exclusive mitogenic driver mutation, more commonly BRAF. BIMTs can occur as a sporadic lesion or, less commonly, in the setting of an autosomal dominant cancer susceptibility syndrome caused by a BAP1 germline inactivating mutation. Owing to the frequent identification of remnants of a conventional nevus, BIMTs are currently classified within the group of combined melanocytic nevi. "Pure" lesions can also be observed. We studied 50 BIMTs from 36 patients. Most lesions were composed of epithelioid melanocytes of varying size and shapes, resulting extreme cytomorphological heterogeneity. Several distinctive morphological variants of multinucleated/giant cells were identified. Some hitherto underrecognized microscopic features, especially regarding nuclear characteristics included nuclear blebbing, nuclear budding, micronuclei, shadow nuclei, peculiar cytoplasmic projections (ant-bear cells) often containing micronuclei and cell-in-cell structures (entosis). In addition, there were mixed nests of conventional and BAP1-inactivated melanocytes and squeezed remnants of the original nevus. Of the 26 lesions studied, 24 yielded a BRAF mutation, while in the remaining two cases there was a RAF1 fusion. BAP1 biallelic and singe allele mutations were found in 4/22 and 16/24 neoplasms, respectively. In five patients, there was a BAP1 germline mutation. Six novel, previously unreported BAP1 mutations have been identified. BAP1 heterozygous loss was detected in 11/22 lesions. Fluorescence in situ hybridization for copy number changes revealed a related amplification of both RREB1 and MYC genes in one tumor, whereas the remaining 20 lesions studied were negative; no TERT-p mutation was found in 14 studied neoplasms. Tetraploidy was identified in 5/21 BIMTs. Of the 21 patients with available follow-up, only one child had a locoregional lymph node metastasis. Our results support a progression of BIMTs from a conventional BRAF mutated in which the original nevus is gradually replaced by epithelioid BAP1-inactivated melanocytes. Some features suggest more complex underlying pathophysiological events that need to be elucidated.
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    12
$a névus $7 D009506
650    12
$a epiteloidní a vřetenobuněčný névus $x genetika $7 D018332
650    12
$a pigmentový névus $x genetika $x patologie $7 D009508
650    _2
$a protoonkogenní proteiny B-raf $x genetika $7 D048493
650    12
$a nádory kůže $x genetika $x patologie $7 D012878
650    _2
$a nádorové supresorové proteiny $x genetika $7 D025521
650    _2
$a thiolesterasa ubikvitinu $x genetika $7 D043222
655    _2
$a časopisecké články $7 D016428
700    1_
$a Martinek, Petr $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Steiner, Petr $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Grossmann, Petr $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Vanecek, Tomas $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Kastnerova, Liubov $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Kolm, Isabel $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
700    1_
$a Baneckova, Martina $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Donati, Pietro $u New Cytology Laboratory, Roma, Italy
700    1_
$a Kletskaya, Irina $u Russian Children's Clinical Hospital of Pirogov Russian National Research Medical University of the Ministry of Healthcare, Russian Federation, Moscow, Russia
700    1_
$a Kalmykova, Antonina $u Laboratory of Pathology, CSD Health Care, Ltd., Kyiv, Ukraine
700    1_
$a Feit, Josef $u Institute of Pathology, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Blasch, Petr $u Department of Pathology, Regional Hospital, Hranice, Czech Republic
700    1_
$a Szilagyi, Diana $u Department of Pathology, Emergency Clinical County Hospital "Pius Brinzeu", Timisoara, Romania
700    1_
$a Baldi, Alfonso $u Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "Luigi Vanvitelli", Caserta, Italy
700    1_
$a Persichetti, Paolo $u Department of Plastic, Reconstructive and Aesthetic Surgery, Campus Bio-Medico di Roma University, Rome, Italy
700    1_
$a Crescenzi, Anna $u Department of Pathology, University Hospital Campus Bio-Medico, Rome, Italy $1 https://orcid.org/0000000281565753
700    1_
$a Michal, Michal $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic $u Bioptical Laboratory, Pilsen, Czech Republic
700    1_
$a Kazakov, Dmitry V $u Sikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic. kazakov@medima.cz $u Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland. kazakov@medima.cz
773    0_
$w MED00003380 $t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc $x 1530-0285 $g Roč. 35, č. 5 (2022), s. 664-675
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34857909 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134916 $b ABA008
999    __
$a ok $b bmc $g 1822307 $s 1169871
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 35 $c 5 $d 664-675 $e 20211202 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace